Rubius Therapeutics Inc.
News
Rubius Therapeutics (NASDAQ:RUBY) and Cardiol Therapeutics (NASDAQ:CRDL) Financial Review
Zolmax Cardiol Therapeutics (NASDAQ:CRDL Get Rating) and Rubius Therapeutics (NASDAQ:RUBY Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ...\n more…
Rubius Therapeutics, Inc. (NASDAQ:RUBY) Short Interest Update
Ticker Report Rubius Therapeutics, Inc. (NASDAQ:RUBY Get Rating) was the target of a large decrease in short interest in February. As of February 15th, there was short interest totalling 1,530,000 shares, a decrease of 18.2% from the January 31st total of 1,870,000 shares. Based on an average trading ...\n more…
Rubius Therapeutics (NASDAQ:RUBY) and Abcam (NASDAQ:ABCM) Head to Head Comparison
Zolmax Rubius Therapeutics (NASDAQ:RUBY Get Rating) and Abcam (NASDAQ:ABCM Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, ...\n more…
Rubius Therapeutics adds 10% on plan for liquidation
Seeking Alpha - Healthcare Rubius Therapeutics (RUBY) jumped ~10% pre-market Wednesday after announcing a plan for liquidation and dissolution subject to shareholder approval. Read the full stoy here.\n more…
Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today?
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nRubius Therapeutics (RUBY) stock is heading higher on Tuesday despite a lack of news from the cellular medicines company.\nThe post Why Is Rubius Therapeutics (RUBY) Stock Up 35% Today? appeared first on InvestorPlace...\n more…